Abstract
Introduction Heart Failure (HF) and Type 2 Diabetes Mellitus (T2DM) frequently coexist and exacerbate symptoms of each other. Treatments are available for T2DM that also provide beneficial treatment effects for HF. Guidelines recommend that patients with HF should be given Sodium-glucose co-transporter-2 inhibitors in preference to other second-line treatments for T2DM. Increasing personalization of treatment means that patients who have or are at risk of HF receive a customised treatment. We aimed to develop and externally validate prediction models to predict the 1-year risk of incident HF in T2DM patients starting second-line treatment.
Methods We analysed a federated network of electronic medical records and administrative claims data from five databases (CCAE, MDCD, MDCR, Optum Clinformatics and Optum EHR) in the United States. We used each database to develop a model to predict 1-year risk of incident HF in patients initialising a second pharmaceutical intervention, following initial treatment with metformin for T2DM. We then performed internal validation for each model as well as external validation using the other databases.
Results A total of 403,187 patients were included in the study. We developed 5 models with discrimination ranging from 0.72 to 0.80 at external validation in the other databases. Consistent high performance was noted for models developed in CCAE, Optum Clinformatics and Optum EHR with AUCs ranging from 0.74 to 0.81. For these models, calibration was acceptable.
Conclusion Three high-performing prediction models were developed for this problem. The CCAE developed model was selected for recommendation as it achieved the same discrimination and better calibration performance than the Optum Clinformatics and Optum EHR models, whilst selecting fewer covariates and as such was selected as the best developed model. The models could be useful in stratifying patient treatment, planning healthcare utilization and reducing cost by aiding in increasing preparedness of healthcare providers.
Competing Interest Statement
JMR and PBR are employees of Janssen Research and Development and shareholders of Johnson and Johnson.
Funding Statement
This project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of IBM and Optum databases were reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to patient privacy concerns no data from the study is available, but upon request access can be discussed. All analysis files and summary statistics form the research will be made available.
